Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Dynamic tailoring of trea… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin

Artikel i vetenskaplig tidskrift
Författare Magnus Lindh
B. Arnholm
P. Bjorkman
Kristoffer Hellstrand
Martin Lagging
Staffan Nilsson
T. Wahlberg
E. Wallmark
O. Weiland
Rune Wejstål
Johan Westin
A. Widell
Gunnar Norkrans
Publicerad i Journal of Viral Hepatitis
Volym 20
Nummer/häfte 4
Sidor e82-e89
ISSN 1352-0504
Publiceringsår 2013
Publicerad vid Institutionen för matematiska vetenskaper, matematisk statistik
Institutionen för biomedicin, avdelningen för infektionssjukdomar
Sidor e82-e89
Språk en
Länkar dx.doi.org/10.1111/jvh.12014
Ämnesord HCV, interferon, kinetics, ribavirin, therapy, early viral kinetics, plus ribavirin, virus, genotype-1, peginterferon, infection, therapy
Ämneskategorier Infektionsmedicin

Sammanfattning

The treatment durations for hepatitis C are guided by the analysis of hepatitis C virus (HCV) RNA in blood at certain time points. This multicentre, randomized open label trial evaluated the utility and performance of individualized treatment durations guided by viral decline rates in 103 patients with HCV genotype 1 infection. Pegylated interferon 2a and ribavirin were given as standard of care (SOC) for 24, 48 or 72 weeks or as dynamic treatment (DT) for 24–72 weeks. The DT duration was based on the time point when log HCV RNA would reach 0 log copies/mL, as estimated by the second-phase decline. The rate of sustained virologic response was 63% for SOC and 54% for DT, but this difference was not significant in multiple regression analysis taking predictive factors such as interleukin-28B genotypes, age and baseline viremia into account (P = 0.45). The mean required treatment time per cured patient was 51 weeks for DT as compared with 58 weeks for SOC (P = 0.22) when given per protocol (n = 95) and was significantly shorter (42 vs 51 weeks) among patients who achieved undetectable HCV RNA (P = 0.01). We conclude that DT was feasible and increased efficiency. The estimated time point for 0 log viral copies/mL is a new and quantitative response variable, which may be used as a complement to the qualitative variable rapid virologic response. The outcome parameter treatment weeks per cured patient could become a useful tool for comparing treatment efficiency also in the era of directly acting antivirals.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?